Chen Xin, Zhang Yazhou, Zhang Nu, Ge Yongsheng, Jia Weidong
Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230001, People's Republic of China.
Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui Province 230001, People's Republic of China.
Onco Targets Ther. 2019 Sep 9;12:7355-7359. doi: 10.2147/OTT.S217123. eCollection 2019.
Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient's condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer.
肝细胞癌（HCC）是一种侵袭性很强的恶性肿瘤。晚期HCC患者的生存率很低。在本病例研究中，我们描述了一名69岁女性巨大肝细胞癌患者的治疗过程，即乐伐替尼联合纳武单抗注射液用于晚期巨大肝细胞癌的术前辅助治疗，最终进行扩大右半肝切除术。分子靶向药物和免疫疗法控制了患者的病情，为手术创造了时间和条件。术后，甲胎蛋白大幅下降，残余肝脏无复发且无远处转移。这种治疗方法是晚期肝癌患者的福音。
